• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparison of in-hospital COVID-19 related outcomes between COVISHIELD and COVAXIN recipients.

作者信息

Suri Tejas M, Ghosh Tamoghna, Arunachalam M, Vadala Rohit, Vig Saurabh, Bhatnagar Sushma, Mohan Anant

机构信息

Department of Pulmonary, Critical Care and Sleep Medicine, All India Institute of Medical Sciences, New Delhi, India.

Department of Pulmonary, All India Institute of Medical Sciences, New Delhi, India.

出版信息

Lung India. 2022 May-Jun;39(3):305-306. doi: 10.4103/lungindia.lungindia_141_22.

DOI:10.4103/lungindia.lungindia_141_22
PMID:35488692
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9200197/
Abstract
摘要

相似文献

1
Comparison of in-hospital COVID-19 related outcomes between COVISHIELD and COVAXIN recipients.接种COVISHIELD疫苗者与接种COVAXIN疫苗者之间新冠肺炎相关院内结局的比较。
Lung India. 2022 May-Jun;39(3):305-306. doi: 10.4103/lungindia.lungindia_141_22.
2
Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines.医护人员接种两剂BBV-152和AZD1222疫苗后针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）刺突糖蛋白抗体的持久性
Front Med (Lausanne). 2021 Dec 22;8:778129. doi: 10.3389/fmed.2021.778129. eCollection 2021.
3
Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin.异源加强 COVID-19 疫苗接种方案的免疫原性和安全性：ChAdOx1 疫苗 Covishield 加 BBV152 疫苗 Covaxin。
J Travel Med. 2021 Dec 29;28(8). doi: 10.1093/jtm/taab166.
4
Humoral Immune Response of SARS-CoV-2 Infection and Anti-SARS-CoV-2 Vaccination in Renal Transplant Recipients.肾移植受者中SARS-CoV-2感染和抗SARS-CoV-2疫苗接种的体液免疫反应
Vaccines (Basel). 2022 Mar 3;10(3):385. doi: 10.3390/vaccines10030385.
5
"Covishield and Covaxin" - India's contribution to global COVID-19 pandemic.“科维希尔德疫苗和科瓦克辛疫苗”——印度对全球新冠疫情的贡献。
J Family Med Prim Care. 2021 Jul;10(7):2433-2435. doi: 10.4103/jfmpc.jfmpc_174_21. Epub 2021 Jul 30.
6
Post immunization COVID-19 disease.免疫后新冠病毒疾病
J Family Med Prim Care. 2022 Apr;11(4):1555-1557. doi: 10.4103/jfmpc.jfmpc_1975_21. Epub 2022 Mar 18.
7
Post-vaccination analysis of anti-spike antibody responses in kidney transplant recipients with and without COVID-19 infection in a tertiary care centre, India.印度一家三级医疗中心对感染和未感染新冠病毒的肾移植受者接种疫苗后抗刺突抗体反应的分析。
Clin Kidney J. 2022 Mar 3;15(7):1312-1321. doi: 10.1093/ckj/sfac057. eCollection 2022 Jul.
8
COVID-19 vaccine hesitancy among medical students in India.印度医学生对 COVID-19 疫苗的犹豫。
Epidemiol Infect. 2021 May 20;149:e132. doi: 10.1017/S0950268821001205.
9
First and second doses of Covishield vaccine provided high level of protection against SARS-CoV-2 infection in highly transmissible settings: results from a prospective cohort of participants residing in congregate facilities in India.科维希尔德疫苗的首剂和第二剂为在高度传染性环境中对 SARS-CoV-2 感染提供了高水平的保护：来自印度聚居设施中居住的参与者的前瞻性队列研究结果。
BMJ Glob Health. 2022 May;7(5). doi: 10.1136/bmjgh-2021-008271.
10
Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study.医护人员接种ChAdOx1 nCoV-19疫苗（COVISHIELD）后的不良事件：一项前瞻性观察研究。
Med J Armed Forces India. 2021 Jul;77(Suppl 2):S283-S288. doi: 10.1016/j.mjafi.2021.06.014. Epub 2021 Jul 26.

引用本文的文献

1
Assessing breakthrough infections: Covishield (late schedule) versus Covaxin - A prospective comparative analysis in the general population.评估突破性感染：Covishield（延迟接种方案）与Covaxin——普通人群中的前瞻性比较分析
J Family Med Prim Care. 2025 Jun;14(6):2307-2312. doi: 10.4103/jfmpc.jfmpc_1714_24. Epub 2025 Jun 6.

本文引用的文献

1
Clinical features, demography, and predictors of outcomes of SARS-CoV-2 infection at a tertiary care hospital in India: A cohort study.印度一家三级护理医院中新冠病毒感染的临床特征、人口统计学及预后预测因素：一项队列研究
Lung India. 2022 Jan-Feb;39(1):16-26. doi: 10.4103/lungindia.lungindia_493_21.
2
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.一种灭活的严重急性呼吸综合征冠状病毒 2 型疫苗（BBV152）的有效性、安全性和批间免疫原性：一项随机、双盲、对照、3 期临床试验的中期结果。
Lancet. 2021 Dec 11;398(10317):2173-2184. doi: 10.1016/S0140-6736(21)02000-6. Epub 2021 Nov 11.
3
Vaccination status and COVID-19 related mortality: A hospital based cross sectional study.疫苗接种状况与新冠病毒相关死亡率：一项基于医院的横断面研究。
Med J Armed Forces India. 2021 Jul;77(Suppl 2):S278-S282. doi: 10.1016/j.mjafi.2021.06.034. Epub 2021 Jul 26.
4
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant.Covid-19 疫苗对 B.1.617.2（德尔塔）变异株的有效性。
N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21.
5
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.